Vicarious Surgical appoints Stephen From as new CEO

WALTHAM, Mass. - Surgical robotics company Vicarious Surgical Inc. (NYSE:RBOT), currently valued at $7.9 million in market capitalization, announced Thursday the appointment of Stephen From as Chief Executive Officer and board member, effective August 7, 2025. Co-founder Adam Sachs will transition from CEO to President while remaining on the company’s board of directors.

From brings over 20 years of healthcare and financial industry leadership experience to the role. He most recently served as CEO of Aruna Bio and previously led Kiora Pharmaceuticals (formerly EyeGate Pharmaceuticals) from 2005 to 2022, where he guided the company through its initial public offering and multiple acquisitions. The appointment comes as Vicarious Surgical maintains a strong liquidity position, with InvestingPro data showing the company’s current ratio at 5.14, indicating robust short-term financial health.

"I am honored to join the Vicarious Surgical team at this pivotal time in its evolution," From said in a statement released by the company.

Sachs, who has led the company since its founding in 2014, expressed confidence in the leadership change: "I believe his leadership and experience are exactly what we need at this pivotal stage."

As part of From’s employment agreement, the company will grant him stock options for 297,600 shares of Class A common stock. The options will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in monthly installments over the following three years.

Vicarious Surgical develops proprietary human-like surgical robots designed to virtually transport surgeons inside patients for minimally invasive procedures. The company aims to increase surgical efficiency, improve patient outcomes, and reduce healthcare costs through its technology.

The company is headquartered in Waltham, Massachusetts, and is backed by investors including Bill Gates and Vinod Khosla’s Khosla Ventures, according to the press release.

In other recent news, Kiora Pharmaceuticals has received a U.S. patent for its KIO-104 treatment, which targets various ocular diseases. The patent, numbered 12,364,680, extends market exclusivity until 2043 and covers treatments for ocular inflammation, uveitis, and age-related macular degeneration, among others. In addition, Kiora Pharmaceuticals has entered into an exclusive option agreement with Senju Pharmaceutical Co., Ltd., potentially worth $110 million. This deal involves the development and commercialization of KIO-301 for ophthalmic diseases in Asia, with Senju paying an initial $1.25 million option fee. The agreement includes additional payments and royalties contingent on development and commercial milestones. Furthermore, Kiora Pharmaceuticals held its annual shareholder meeting, confirming the election of Carmine Stengone and Brian M. Strem, Ph.D., as Class I Directors for three-year terms. These developments highlight Kiora Pharmaceuticals’ ongoing efforts in advancing its treatment portfolio and strategic collaborations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.